3 results about "Drug Substitution" patented technology

This invention belongs to the field of acute lymphoblastic leukemia (ALL) technology and discloses an ALL scoring system. The system divides the entire treatment cycle into three major phases: induction remission, consolidation therapy, and maintenance therapy. Each phase is further subdivided into sub-phases, forming a two-tiered data acquisition architecture. During data collection, baseline data such as age and fusion genes are included, along with dynamic data such as the rate of MRD decline and drug exposure concentration. Simultaneously, anchor triggering mechanisms are set at different sub-phases, making the risk score more closely aligned with the patient's real-time condition and providing a more accurate reference for clinical treatment strategy selection. The feature adaptation module matches subtype-specific biomarkers and analyzes the interaction between rare subtypes and comorbidities. The matching module calls upon a three-dimensional protocol library to select standardized protocols for common subtypes, targeted protocols for rare subtypes, and dose adjustment or drug substitution protocols for patients with comorbidities, matching more suitable protocols for different patients.

The present application relates to gamma aminobutyric acid analogues and methods of making and using the same. The gamma aminobutyric acid analogues include a gamma aminobutyric acid moiety and a polyethylene glycol (PEG) moiety. The gamma aminobutyric acid analogues of the present application are active GABA analogues that promote proliferation of pancreatic beta cells and secretion of insulin, have similar in vivo functions as GABA, improve in vivo metabolic characteristics relative to GABA, and are useful as drug substitutes for treating metabolic and neurological diseases.